Cellectis (CLLS) Dropped Sharply After FDA Clinical Hold

Cellectis (CLLS) announced Tuesday morning that the FDA has placed a clinical hold on both of its UCART123 ongoing Phase 1 studies after the death of one patient.

from RTT - Before the Bell http://ift.tt/2xOJKYC
via IFTTT